S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma (2015/1/22)|
|CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer) (2015/1/6)|
|CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma (KS) (2015/1/8)|
|CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients (2015/1/20)|
|CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials (2014/12/3)|
|CytRx to Present at the Oppenheimer 25th Annual Healthcare Conference (2014/12/2)|
|CytRx to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015 in New York City (2015/2/2)|
|CytRx to Present at the Cowen & Company 35th Annual Health Care Conference (2015/2/25)|
Click above to view more mutual fund data and stats for cytr - CytRx Corp.